AL Amyloidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major AL amyloidosis markets reached a value of US$ 3,374.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 13,300.4 Million by 2034, exhibiting a growth rate (CAGR) of 13.1% during 2024-2034.
The AL amyloidosis market has been comprehensively analyzed in IMARC's new report titled "AL Amyloidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". AL amyloidosis, also referred to as primary amyloidosis, is a rare ailment characterized by the abnormal accumulation of amyloid proteins. It can cause a wide range of symptoms depending on the organs and tissues affected by the amyloid deposits. The most commonly impacted organs are the heart, kidneys, liver, and nervous system, and indications may include fatigue, shortness of breath, swelling in the legs and ankles, irregular heartbeat, chest pain, difficulty swallowing, nausea, vomiting, diarrhea, weight loss, etc. As the disease progresses, it can lead to organ failure, which can be life-threatening. The diagnosis of AL amyloidosis can be challenging, as its symptoms are often non-specific and can mimic other common conditions. Physicians typically start with a thorough medical history and physical exam, followed by blood and urine tests to look for abnormal protein levels and evidence of organ damage. A biopsy of affected tissue is usually necessary to confirm the presence of amyloid fibrils and to determine the specific type of amyloidosis. Several imaging tests, such as echocardiograms and CT scans, may also be used to evaluate the extent of organ involvement.
The increasing cases of mutations in the DNA of plasma cells and the rising incidence of underlying plasma cell disorders, such as multiple myeloma and monoclonal gammopathy of undetermined significance, are primarily driving the AL amyloidosis market. In addition to this, the widespread adoption of amyloid stabilizers, which stabilize the amyloid protein and prevent it from accumulating in tissues and organs, for treating the ailment is further bolstering the market growth. Moreover, the escalating utilization of novel agents, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, etc., which target the underlying mechanisms of AL amyloidosis, has significantly improved response rates and prolonged progression-free survival in patients. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of high-dose chemotherapy, followed by autologous stem cell transplantation, as a treatment option for eligible patients with AL amyloidosis is also propelling the market growth. This procedure aims to eliminate abnormal cells that produce the amyloid protein and improve organ function. Furthermore, the ongoing advancements in diagnostic techniques, such as the introduction of serum-free light chain assays and mass spectrometry, have facilitated earlier diagnosis, allowing for prompt initiation of treatment and better management of disease-related complications. This, in turn, is expected to drive the AL amyloidosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the AL amyloidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for AL amyloidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the AL amyloidosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the AL amyloidosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the AL amyloidosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current AL amyloidosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the AL amyloidosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the AL amyloidosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the AL amyloidosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of AL amyloidosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of AL amyloidosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of AL amyloidosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with AL amyloidosis across the seven major markets?
What is the size of the AL amyloidosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of AL amyloidosis?
What will be the growth rate of patients across the seven major markets?
AL Amyloidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for AL amyloidosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the AL amyloidosis market?
What are the key regulatory events related to the AL amyloidosis market?
What is the structure of clinical trial landscape by status related to the AL amyloidosis market?
What is the structure of clinical trial landscape by phase related to the AL amyloidosis market?
What is the structure of clinical trial landscape by route of administration related to the AL amyloidosis market?
The AL amyloidosis market has been comprehensively analyzed in IMARC's new report titled "AL Amyloidosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". AL amyloidosis, also referred to as primary amyloidosis, is a rare ailment characterized by the abnormal accumulation of amyloid proteins. It can cause a wide range of symptoms depending on the organs and tissues affected by the amyloid deposits. The most commonly impacted organs are the heart, kidneys, liver, and nervous system, and indications may include fatigue, shortness of breath, swelling in the legs and ankles, irregular heartbeat, chest pain, difficulty swallowing, nausea, vomiting, diarrhea, weight loss, etc. As the disease progresses, it can lead to organ failure, which can be life-threatening. The diagnosis of AL amyloidosis can be challenging, as its symptoms are often non-specific and can mimic other common conditions. Physicians typically start with a thorough medical history and physical exam, followed by blood and urine tests to look for abnormal protein levels and evidence of organ damage. A biopsy of affected tissue is usually necessary to confirm the presence of amyloid fibrils and to determine the specific type of amyloidosis. Several imaging tests, such as echocardiograms and CT scans, may also be used to evaluate the extent of organ involvement.
The increasing cases of mutations in the DNA of plasma cells and the rising incidence of underlying plasma cell disorders, such as multiple myeloma and monoclonal gammopathy of undetermined significance, are primarily driving the AL amyloidosis market. In addition to this, the widespread adoption of amyloid stabilizers, which stabilize the amyloid protein and prevent it from accumulating in tissues and organs, for treating the ailment is further bolstering the market growth. Moreover, the escalating utilization of novel agents, including proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, etc., which target the underlying mechanisms of AL amyloidosis, has significantly improved response rates and prolonged progression-free survival in patients. This, in turn, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of high-dose chemotherapy, followed by autologous stem cell transplantation, as a treatment option for eligible patients with AL amyloidosis is also propelling the market growth. This procedure aims to eliminate abnormal cells that produce the amyloid protein and improve organ function. Furthermore, the ongoing advancements in diagnostic techniques, such as the introduction of serum-free light chain assays and mass spectrometry, have facilitated earlier diagnosis, allowing for prompt initiation of treatment and better management of disease-related complications. This, in turn, is expected to drive the AL amyloidosis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the AL amyloidosis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for AL amyloidosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the AL amyloidosis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the AL amyloidosis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the AL amyloidosis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current AL amyloidosis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the AL amyloidosis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the AL amyloidosis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the AL amyloidosis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of AL amyloidosis across the seven major markets?
What is the number of prevalent cases (2018-2034) of AL amyloidosis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of AL amyloidosis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with AL amyloidosis across the seven major markets?
What is the size of the AL amyloidosis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of AL amyloidosis?
What will be the growth rate of patients across the seven major markets?
AL Amyloidosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for AL amyloidosis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the AL amyloidosis market?
What are the key regulatory events related to the AL amyloidosis market?
What is the structure of clinical trial landscape by status related to the AL amyloidosis market?
What is the structure of clinical trial landscape by phase related to the AL amyloidosis market?
What is the structure of clinical trial landscape by route of administration related to the AL amyloidosis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AL AMYLOIDOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AL AMYLOIDOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AL AMYLOIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 AL AMYLOIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AL AMYLOIDOSIS - UNMET NEEDS
10 AL AMYLOIDOSIS - KEY ENDPOINTS OF TREATMENT
11 AL AMYLOIDOSIS - MARKETED PRODUCTS
11.1 List of AL Amyloidosis Marketed Drugs Across the Top 7 Markets
11.1.1 Darzalex Faspro (Daratumumab/hyaluronidase) - Janssen Biotech
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AL AMYLOIDOSIS - PIPELINE DRUGS
12.1 List of AL Amyloidosis Pipeline Drugs Across the Top 7 Markets
12.1.1 CAEL-101 - Caelum Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NEOD 001 - Prothena
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ZN d5 - Zentera Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 STI-6129 - Sorrento Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. AL AMYLOIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AL AMYLOIDOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AL AMYLOIDOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 AL Amyloidosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 AL Amyloidosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 AL Amyloidosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 AL Amyloidosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 AL Amyloidosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 AL Amyloidosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 AL Amyloidosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 AL Amyloidosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 AL Amyloidosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 AL Amyloidosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 AL Amyloidosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 AL Amyloidosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 AL Amyloidosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 AL Amyloidosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 AL Amyloidosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 AL Amyloidosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 AL Amyloidosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 AL Amyloidosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 AL Amyloidosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 AL Amyloidosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 AL Amyloidosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 AL Amyloidosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 AL Amyloidosis - Access and Reimbursement Overview
16 AL AMYLOIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AL AMYLOIDOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AL AMYLOIDOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 AL AMYLOIDOSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 AL AMYLOIDOSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 AL AMYLOIDOSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 AL AMYLOIDOSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 AL AMYLOIDOSIS - UNMET NEEDS
10 AL AMYLOIDOSIS - KEY ENDPOINTS OF TREATMENT
11 AL AMYLOIDOSIS - MARKETED PRODUCTS
11.1 List of AL Amyloidosis Marketed Drugs Across the Top 7 Markets
11.1.1 Darzalex Faspro (Daratumumab/hyaluronidase) - Janssen Biotech
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 AL AMYLOIDOSIS - PIPELINE DRUGS
12.1 List of AL Amyloidosis Pipeline Drugs Across the Top 7 Markets
12.1.1 CAEL-101 - Caelum Biosciences
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 NEOD 001 - Prothena
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 ZN d5 - Zentera Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 STI-6129 - Sorrento Therapeutics
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. AL AMYLOIDOSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. AL AMYLOIDOSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 AL AMYLOIDOSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 AL Amyloidosis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 AL Amyloidosis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 AL Amyloidosis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 AL Amyloidosis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 AL Amyloidosis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 AL Amyloidosis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 AL Amyloidosis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 AL Amyloidosis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 AL Amyloidosis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 AL Amyloidosis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 AL Amyloidosis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 AL Amyloidosis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 AL Amyloidosis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 AL Amyloidosis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 AL Amyloidosis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 AL Amyloidosis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 AL Amyloidosis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 AL Amyloidosis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 AL Amyloidosis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 AL Amyloidosis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 AL Amyloidosis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 AL Amyloidosis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 AL Amyloidosis - Access and Reimbursement Overview
16 AL AMYLOIDOSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 AL AMYLOIDOSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 AL AMYLOIDOSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
